Sharon Cheetham is a Board Director and Cofounder of RenaSci Ltd, a specialist provider of experimental and consultancy services investigating metabolic and central nervous system (CNS) disorders.
She is also an Assistant Professor at the University of Nottingham.
Cheetham started her research career studying epilepsy at the Institute of Psychiatry, University of London. She earned her Doctorate at St George’s Hospital, London, for her dissertation, "Neurotransmitters and their receptors in post mortem brain from depressed suicide victims."
Cheetham transitioned from academia to the business industry in 1988, when she joined Boots Pharmaceuticals (then BASF Pharma) where she led a team evaluating novel CNS treatments for obesity, making a major contribution to the discovery, development and registration of sibutramine within Europe and U.S. In 2001, she and two colleagues founded the niche contract research organization RenaSci Ltd, which with over 35 employees was recently acquired by Sygnature Discovery.
Board Director and Cofounder